Detailed information of tisa-cel therapy and related events
| CD19 CAR-T characteristics . | Result . |
|---|---|
| Time from last nontransplant therapy to CAR T-cell infusion, n (%) median (IQR), mo | 17.9 (5.1-44.5) |
| Time from diagnosis to tisa-cel infusion, n (%) median (IQR), mo | 31.8 (12.2-59.9) |
| Time from last HCT to tisa-cel infusion, median (IQR), mo | 14.5 (9.2-21.3) |
| LD chemotherapy, n (%) | |
| Cyclophosphamide + fludarabine | 465 (98.7) |
| Other∗ | 6 (1.3) |
| Median time between start of LD chemotherapy to CAR T-cell therapy infusion (IQR), d | 6.0 (6.0-7.0) |
| Median total tisa-cel cell dose, median (IQR) | 1.4 × 108 (0.42 × 108 to 5.4 × 108) |
| Time from tisa-cel infusion to neutrophil recovery (event only), median (IQR), d | 14.0 (9.0-21.0) |
| Time from tisa-cel infusion to CRS onset (event only), median (IQR), d | 5.0 (2.0-7.0) |
| IV IgG replacement given, n (%) | 165 (35.0) |
| IgG <600 mg/dL, n (%) | 322 (68.4) |
| Severity of CRS† , n (%) | |
| Grade 0 | 193 (41.0) |
| Grade 1-2 | 178 (37.8) |
| Grade ≥3 | 88 (18.7) |
| Not reported | 12 (2.5) |
| Time from tisa-cel infusion to ICANS onset (event only), median (IQR), d | 7.0 (5.0-9.0) |
| Severity of ICANS† | |
| Grade 0 | 349 (74.1) |
| Grade 1-2 | 13 (2.8) |
| Grade ≥3 | 33 (6.9) |
| Not reported | 76 (16.1) |
| Corticosteroid use, n (%) | |
| No | 379 (80.5) |
| Yes | 62 (13.2) |
| Missing | 30 (6.4) |
| Tocilizumab use, n (%) | |
| No | 304 (64.5) |
| Yes | 148 (31.4) |
| Missing | 19 (4.0) |
| Therapy given for CRS: anakinra, n (%) | |
| No | 274 (58.2) |
| Yes | 3 (0.6) |
| Not reported | 194 (41.2) |
| Therapy given for CRS: siltuximab, n (%) | |
| No | 262 (55.6) |
| Yes | 15 (3.2) |
| Not reported | 194 (41.2) |
| History of acute GVHD in patients who received tisa-cel infusion after HCT, n (%) | 25 (22.1) |
| History of chronic GVHD in patients who received tisa-cel infusion after HCT, n (%) | 31 (27.4) |
| Year of tisa-cel therapy, n (%) | |
| 2017-2019 | 331 (70.3) |
| 2020-2022 | 140 (29.7) |
| Follow-up of survivors, median (range), mo | 29.7 (3.0-59.5) |
| CD19 CAR-T characteristics . | Result . |
|---|---|
| Time from last nontransplant therapy to CAR T-cell infusion, n (%) median (IQR), mo | 17.9 (5.1-44.5) |
| Time from diagnosis to tisa-cel infusion, n (%) median (IQR), mo | 31.8 (12.2-59.9) |
| Time from last HCT to tisa-cel infusion, median (IQR), mo | 14.5 (9.2-21.3) |
| LD chemotherapy, n (%) | |
| Cyclophosphamide + fludarabine | 465 (98.7) |
| Other∗ | 6 (1.3) |
| Median time between start of LD chemotherapy to CAR T-cell therapy infusion (IQR), d | 6.0 (6.0-7.0) |
| Median total tisa-cel cell dose, median (IQR) | 1.4 × 108 (0.42 × 108 to 5.4 × 108) |
| Time from tisa-cel infusion to neutrophil recovery (event only), median (IQR), d | 14.0 (9.0-21.0) |
| Time from tisa-cel infusion to CRS onset (event only), median (IQR), d | 5.0 (2.0-7.0) |
| IV IgG replacement given, n (%) | 165 (35.0) |
| IgG <600 mg/dL, n (%) | 322 (68.4) |
| Severity of CRS† , n (%) | |
| Grade 0 | 193 (41.0) |
| Grade 1-2 | 178 (37.8) |
| Grade ≥3 | 88 (18.7) |
| Not reported | 12 (2.5) |
| Time from tisa-cel infusion to ICANS onset (event only), median (IQR), d | 7.0 (5.0-9.0) |
| Severity of ICANS† | |
| Grade 0 | 349 (74.1) |
| Grade 1-2 | 13 (2.8) |
| Grade ≥3 | 33 (6.9) |
| Not reported | 76 (16.1) |
| Corticosteroid use, n (%) | |
| No | 379 (80.5) |
| Yes | 62 (13.2) |
| Missing | 30 (6.4) |
| Tocilizumab use, n (%) | |
| No | 304 (64.5) |
| Yes | 148 (31.4) |
| Missing | 19 (4.0) |
| Therapy given for CRS: anakinra, n (%) | |
| No | 274 (58.2) |
| Yes | 3 (0.6) |
| Not reported | 194 (41.2) |
| Therapy given for CRS: siltuximab, n (%) | |
| No | 262 (55.6) |
| Yes | 15 (3.2) |
| Not reported | 194 (41.2) |
| History of acute GVHD in patients who received tisa-cel infusion after HCT, n (%) | 25 (22.1) |
| History of chronic GVHD in patients who received tisa-cel infusion after HCT, n (%) | 31 (27.4) |
| Year of tisa-cel therapy, n (%) | |
| 2017-2019 | 331 (70.3) |
| 2020-2022 | 140 (29.7) |
| Follow-up of survivors, median (range), mo | 29.7 (3.0-59.5) |
GVHD, graft-versus-host disease; LD, lymphodepleting.
Other regimens included: cytarabine + fludarabine (1), clofarabine + fludarabine (1) and cyclophosphamide + cytarabine + fludarabine (1), fludarabine only (1), not specified (2).
Severity grading according to the American Society of Transplant and Cellular Therapy consensus criteria.